A carregar...
Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions
Cabozantinib, a c-MET and vascular endothelial growth factor receptor 2 inhibitor, demonstrated to prolong progression free survival and improve skeletal disease-related endpoints in castration-resistant prostate cancer and in metastatic renal carcinoma. Our purpose is to investigate the direct effe...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5386748/ https://ncbi.nlm.nih.gov/pubmed/28223547 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15390 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|